What's ahead for veterinary pharma

The advances in veterinary pharmacology are transforming treatment delivery and improving bioavailability and efficacy. The goal: enhanced patient outcomes, caregiver convenience, and compliance.

Researchers working in a science lab.
Photo courtesy Boehringer Ingelheim

This is an exciting time in veterinary pharmacology. Precision medicine tailored to specific species, novel therapeutic agents, long-acting injectable formulations, and targeted treatment options for conditions ranging from infectious diseases to cancer are here, with more developments in progress. The advances are transforming treatment delivery, improving bioavailability and efficacy, and minimizing dosing frequency. The goal: enhanced patient outcomes and caregiver convenience and compliance.

Challenges remain, however. Research and development are expensive and time-consuming. It can take up to 10 years and countless dollars to bring a new medication to market. On the consumer side, the rising cost of veterinary care can be a significant barrier to care. Staying ahead of drug resistance is also an ongoing concern. Let's look at what experts see now and for the future.

Challenges and opportunities

Veterinary pharma companies must look beyond current advances, anticipate the direction of change, and adapt quickly—all while meeting the strict requirements of pharmaceutical development. They must be tuned to the market—which differs across countries—understand the biology of diseases in areas of focus, choose therapies to develop that will make a difference and change how medicine is practiced, and find and involve patients and organize clinical trials. Those are just a few of the challenges.

"There's a lot of work beyond the actual development of the drug to do the right thing for our customers and our profession," says Richard Goldstein, DVM, senior vice president, global chief medical officer, and head of medical affairs at Zoetis.

One ongoing challenge is the substantial investment in time and money required to bring a new medicine from the laboratory to the veterinary clinic. Animal diseases are complex, but the rapid emergence of digital science and artificial intelligence holds promise to accelerate certain aspects of the research and development process, says Peter Florian, Dr. med. vet., head of research for Boehringer Ingelheim Animal Health.

As dogs and cats live longer, chronic diseases become more common, Dr. Florian says. "We see significant potential to seek opportunities for innovation in our R&D process by clearly defining where chronic disease characteristics in areas of high unmet need match potential molecular targets for therapeutic intervention."

Drug delivery details

New and emerging medication administration options include microneedle patches, flavored tablets and soft chews, and dissolvable films.

"When we think of innovation and veterinary medicine, we're thinking about new therapeutic areas, novel targets, and new technology platforms like monoclonal antibodies and immunotherapeutics, but it might also be routes of administration and duration of activity—things that help the veterinarian address client compliance and convenience to the pet owner," says Mayur Patel, DVM, vice president for global R&D product development, strategy, and innovation portfolio management at Elanco Animal Health.

Microneedle technology is minimally invasive and enables controlled and sustained drug release, providing effective and long-lasting pain management.1 Veterinary use remains limited, but studies indicate promising applications in pain management, vaccination, diagnostics, and dermatological therapy.2

Chewable medications have been available for a long time, and veterinarians rely on them to deliver relief to pets whose owners have difficulty giving them pills. Studies show medicated treats and chewable oral formulations may improve owner compliance with treatment because both the owner and the pet experience less stress.3 The result tends to be improved dosing and increased therapeutic success.

Palatability and bioavailability have been issues in the past, but technology, such as food-based matrices and a focus on texture and aroma, is addressing those concerns.

Improving bioavailability is an additional aid to product performance. At Virbac, researchers learned of a molecule, ursolic acid (UA), that targets causes of muscle atrophy by counteracting atrophy-associated mRNA expression. UA is a well-known, naturally occurring plant triterpenoid found in sage, rosemary, and apple peels; however, its poor bioavailability has previously been a limiting factor to its use in companion animals.4

In collaboration with the human biotech company Emmyon, Virbac worked to develop a muscle-support chew featuring UA with a coating that surrounds the UA molecule, thereby increasing solubility and improving dissolution in the body. This proprietary coating enables a fourfold increase in peak plasma concentration in canine bioavailability trials compared with uncoated UA, while masking the compound's bitter botanical profile.5 If the animal gulps the entire chew instead of chewing it, the supplement should still be appropriately absorbed, says Nancy Turner, DVM, a medical consulting veterinarian for the company's product safety and consulting team.

Some chewable challenges

Chewing action is essential for removing plaque and tartar. It also helps activate the substances in them that prevent plaque and tartar buildup. Turner urges veterinarians to make sure owners provide pets with chews of the appropriate size so they can't be swallowed in a single gulp.

Additionally, she hopes veterinarians will recommend these types of products earlier in a pet's life to get a head start in the fight against chronic aging conditions, such as dental disease and poor mobility.

"The Senior Dog Veterinary Society is working to develop messaging and protocol developments for general practitioners around having those conversations earlier so we can make a bigger impact and keep those dogs out of that chronic disease state for as long as possible," Turner says.

Other chewable challenges include dose uniformity, physicochemical stability, microbiological safety, and regulatory classification. It's not easy to take something that works well on a small scale and mass-produce with quality in a way that's accepted by regulatory authorities around the world," Dr. Goldstein says.

Cats and palatability

In companion animals, palatability is critical to treatment adherence. Modifying texture, shape, color, and format, and incorporating species-specific flavor profiles are among the ways manufacturers enhance acceptance.

Cats are notoriously reluctant to take unfamiliar foods or medications. In Virbac's nationwide Ursolyx Soft Chews for Cats user trial, 82 percent of cat owner participants said the chew was easy to give, Dr. Turner says.

"Cats are so particular. Almost every cat has a different preference as far as textures," she says. "Some cats are much more likely to take a softer chew, and others prefer something crunchy. For cats, 82 percent is great, but they're a tough crowd for sure."

Long-acting injectables and more

Long-acting injectables have been an important development in areas including pain management, antibiotics, anti-parasitics, and dermatology. They extend the duration of effect, providing a steady and consistent dose without the need to administer multiple doses. Sustained-release delivery makes them ideal for managing chronic conditions. Fewer veterinary visits are a plus for clients and patients.

"Injectables allow the veterinarian to see the patient, assess how they're doing, and provide the therapies in a long-acting, consistent way," Goldstein says.

Recenty, Zoetis Inc. announced that the U.S. Department of Agriculture (USDA) has licensed Cytopoint Plus for the treatment of allergic dermatitis in dogs. The monoclonal antibody (mAb) is administered by subcutaneous injection every 75 days as needed, reportedly providing the longest dosing interval among licensed mAb treatments for canine allergic dermatitis.

Itchy pets are among the beneficiaries of long-acting injectables. Nearly nine out of 10 dogs in the U.S. experience some level of itch, says Jennifer Miller, DVM, medical strategy lead for U.S. dermatology at Elanco Animal Health. That was the finding of the company's Itchy Dog Report, based on multiple surveys of pet owners and veterinarians.

It's not surprising then that anti-itch products are a mainstay in the nearly $1.3 billion U.S. dermatology market. Advances in this area include monoclonal antibody injections that target causes of itch. One such product is Elanco's Befrena (tirnovetmab), which received USDA approval on December 31, 2025. It is aimed at canine allergic and atopic dermatitis, with recommended dosing intervals of six to eight weeks post-treatment.

Clients tend to wait six weeks to take itchy pets to the veterinarian, according to Elanco's survey results, and when they do, they want fast results if OTC remedies have failed.

"They're only giving that veterinarian around three opportunities to get that dog's itch under control before they're 'quiet quitting' and going to another clinic," Dr. Miller says. "We need to have products that are efficacious from the beginning to provide relief for these itchy dogs."

More recently, Vetoquinol USA, Inc., announced that Felpreva (emodepside, praziquantel, and tigolaner topical solution) received approval from the U.S. Food & Drug Administration (FDA).

The prescription-only broad-spectrum parasiticide for cats combines three active ingredients: emodepside to treat roundworms; praziquantel to treat tapeworms; and tigolaner to control fleas, ticks, and mites. It reportedly treats and prevents fleas and treats and controls black-legged ticks for 12 weeks; treats and controls lone star ticks for eight weeks in feline patients at least six months of age, weighing at least 2.2 lb.

New types of vaccines

Vaccines are classic long-term injectables for disease prevention, but researchers are now exploring ways to use them to improve outcomes for certain cancers, inflammatory diseases, and equine dermatological conditions, the latter of which is a high unmet need in horses.

For instance, Boehringer Ingelheim's therapeutic vaccine platform uses virus-like particles to produce neutralizing antibodies against disease-related proteins. The idea is to use a virus-like particle decorated with an antigen to stimulate the animal's immune system and generate neutralizing monoclonal antibody responses, potentially resulting in a longer duration of action, Dr. Florian says.

At the University of Florida (UF) College of Veterinary Medicine, researchers have had a long-term focus on developing vaccines against aggressive cancers such as osteosarcoma, oral melanoma, and hemangiosarcoma. Those cancers were not very responsive to chemotherapy, and there weren't a lot of other tools to fight them.

Precision medicine techniques, immune checkpoint inhibitors, such as Merck's gilvetmab,6 and immunotherapy vaccines have all played a role in the search for treatments. The university currently has five cancer vaccine studies7 in which dogs can participate, plus two other oncology studies also enrolling dogs.

Rowan J. Milner, BVsc (Hons), MMedVet DECVIM (Oncology), DACVIM (Oncology), PhD, director of clinical and translational research at UF College of Veterinary Medicine, is excited about their progress.

"There are a lot of dogs with melanoma and these other cancers," he says. "I think an off-the-shelf vaccine like this would make a difference. I think it is important to get across, however, that giving this vaccine is not going to stop a dog from getting new melanomas. It's not a preventative."

Treatments for gliomas, aggressive brain tumors that affect humans and dogs, are also being investigated at UF. Brachycephalic breeds, such as boxers, bulldogs, and Boston terriers, have a higher incidence of these tumors, and there is not a standard of care, says Sheila Carrera-Justiz, DVM, DACVIM, clinical associate professor and service chief, neurology and orthopedics, at UF College of Veterinary Medicine. A number of clinical trials at different institutions are studying the tumors, and dogs benefit because they are naturally occurring models.

"Because these are studies that are funded, people have the opportunity for their dogs to receive treatment, many times at no cost to them," she says. "They're focusing on immunotherapy, aiming to use the immune system to fight off the cancer."

Dr. Carrera-Justiz encourages practitioners to reach out to neurologists for help on a case and get more information for themselves and for their clients.

A collage of a male and female veterinarian each holding canine patients.
Drs. Rowan J. Milner and Sheila Carrera-Justiz of the University of Florida (UF) College of Veterinary Medicine share their thoughts about the advancements in cancer research through innovative vaccine studies, immunotherapy, and clinical trials at UF. Photos courtesy University of Florida College of Veterinary Medicine

Old drug, new use

There's lots of crossover between human and animal pharmacology. Often, medications for humans are used off-label in companion animals, but some make the leap and are approved for both.

Convergence of human and animal drugs has become an important complementary approach in pharmacological innovation. Therapeutic extensions and drug repositioning have the potential to play an important role in veterinary medicine, particularly in challenging therapeutic areas, such as oncology.

An example is the use of COX-2 inhibitors, such as meloxicam and deracoxib, to treat canine cancers, and big data has enabled significant progress in finding and choosing candidates for drug repositioning. Retrospective analysis of patient data stored in electronic health records can identify unexpected beneficial effects of drugs in therapeutic areas different from the original use.8

"Our R&D organization is strongly partnered with our human pharma R&D organization," Florian says. "That really helps us to leverage such know-how early on and then consider future innovation potential during the phase of identifying molecules, lead structures, and then following up with animal health-specific molecules for the application to companion animals or horses."

A new therapeutic extension benefiting cats is the recent approval of amlodipine (Amodip), a chewable tablet for managing feline hypertension. From Ceva Animal Health, it is the first FDA-approved amlodipine product specifically formulated for cats. Amlodipine has been used off-label in hypertensive cats for years, but it is no longer necessary for caretakers to split human tablets into quarters for them—thereby increasing the risk of dosing inaccuracy—or to purchase compounded formulations.9

Future tech

AI is making rapid headway in veterinary medicine in both research and diagnostics. Boehringer is in the early stages of applying robotic phenotypic screening, which uses robots, imaging, and artificial intelligence to observe how parasites respond to potential new drug candidates, to help find new ways to address parasite resistance. On the cardiology front, Florian is excited about a collaboration with Eko Health that launched a technology to help veterinarians detect, visualize, and grade heart murmurs in dogs.10

A dog and its veterinarian and owner.
Eko Vet+TM | CANINEBEAT® AI is a new technology launched by Boehringer Ingelheim and Eko Health to help veterinarians detect, visualize, and grade heart murmurs in dogs. Photo courtesy Boehringer Ingelheim

Florian believes future veterinarians will focus less on treating disease and more on predicting, preventing, detecting, and managing health risk throughout an animal's life. With more complex diagnostics, they can better identify patients most at risk for disease progression.

Another development is that senior pets are taking center stage.

"As a profession, we're moving much more into dealing with the mature pet, the geriatric pet," Goldstein says. "We're talking now not only about lifespan, but also health span—how many years of good-quality life they have. There's a huge opportunity there to make a big difference in how these patients are managed and provide a much longer and happier life to these pets."


Kim Campbell Thornton has been writing about dogs, cats, wildlife, and marine life since 1985, and is a recipient of multiple awards for her articles and books from the Cat Writers Association, Dog Writers Association of America, and the American Society of Journalists and Authors.

References

  1. Miranda-Muñoz, K.A., Tsai, T., Powell, J.G. et al. Advances in veterinary drug and vaccine delivery: from conventional delivery methods to innovative transdermal approaches. Drug Deliv. and Transl. Res. 16, 3169–3200 (2026). https://doi.org/10.1007/s13346-026-02105-w
  2. Justyna, Ś. Patrycja, and W. Rafał, " From Human to Veterinary Medicine: Expanding the Role of Microneedle Drug Delivery and Diagnostic Systems." Advanced Materials Technologies 11, no. 12 (2026): e02478. https://doi.org/10.1002/admt.202502478
  3. dos Santos, M. G., Andrade, J. F., & Feitosa, V. A. (2026). Oral drug delivery systems for companion animals: an integrative review of medicated treats, chewable tablets, and other pharmaceutical formulations. Brazilian Journal of Veterinary Medicine, 48, e004226. https://doi.org/10.29374/2527-2179.bjvm004226
  4. https://www.emmyon.com/natural-compounds/
  5. https://vet-us.virbac.com/files/live/sites/virbac-b2b-usa/files/client-leaflet/Products/URSOLYX%E2%84%A2%20Soft%20Chews/Ursolic%20Acid%20for%20Improved%20Absorption%20and%20Palatability.pdf
  6. Esther Chon, Mohamad Morsey, Terry Katz, Kazumi Yamada, Dennis Bailey, Philip J Bergman, Holly Burr, Craig A Clifford, Heather Heeb, Christina Manley, Brenda Phillips, Gerald Post, David M Vail, Anthony Rusk, Matthew L Stock, Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor, Journal of Veterinary Internal Medicine, Volume 40, Issue 3, May-June 2026, aalag098, https://doi.org/10.1093/jvimsj/aalag098
  7. https://research.vetmed.ufl.edu/research-programs/clinical-trials/oncology/
  8. Mag, P.; Nemes-Terényi, M.; Jerzsele, Á.; Mátyus, P. Some Aspects and Convergence of Human and Veterinary Drug Repositioning. Molecules 2024, 29, 4475. https://doi.org/10.3390/molecules29184475
  9. https://vetmedguide.com/blog/amodip-amlodipine-for-cats-feline-hypertension
  10. https://caninebeat.com/

 

Comments
Post a Comment

Comments